

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL	60	-	60	=	0	\$ 18	\$0.00
INDEPENDENT	2	-	3	=	0	\$ 84	\$0.00
____ FIRST PRESENTATION OF A MULTIPLE CLAIM						\$270	\$0.00
						TOTAL	\$0.00

Docket No. 0147-0221P

- ☐ Petition for ( ) month(s) extension of time pursuant to 37 C.F.R. §§ 1.17 and 1.136(a). \$0.00 for the extension of time.
- ☒ No fee is required.
- ☐ A check in the amount of \$0.00 is enclosed.
- ☐ Please charge Deposit Account No. 02-2448 in the amount of \$0.00. This form is submitted in triplicate.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. §§1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP


By *my N. all* 36,623  
Leonard R. Svensson, #30,330

LRS/BCF  
0147-0221P

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

Attachment

(Rev. 01/22/01)



BOX SEQUENCE  
PATENT  
0147-0221P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: SPIESS, Joachim et al. Conf.: 5077  
Appl. No.: 09/744,441 Group: UNASSIGNED  
Filed: May 11, 2001 Examiner: UNASSIGNED  
For: ANTAGONISTS SPECIFIC FOR THE CORTICOTROPIN-  
RELEASING FACTOR RECEPTOR TYPE 2 (CRFR2)

AMENDMENT

Assistant Commissioner for Patents  
Washington, DC 20231

November 6, 2002

Sir:

In response to the Notification of Defective Response mailed October 7, 2002, the following amendments and remarks are respectfully submitted in connection with the above-identified application.

In the Specification:

Please replace the paragraph on page 4 line 27 with the following amended paragraph:

-- In a more preferred embodiment the antagonist of the present invention comprises the amino acid sequence Xaa<sub>1</sub>-Xaa<sub>2</sub>-Leu-Leu-Arg-Lys-Met-Ile-Glu-Ile-Glu-Lys-Gln-Glu-Lys-Glu-Lys-Gln-Gln-Ala-Ala-Asn-Asn-Arg-Leu-Leu-Leu-Asp-Thr-Ile-NH<sub>2</sub> (SEQ ID NO: 1), wherein Xaa<sub>1</sub> is a neutral amino acid, and Xaa<sub>2</sub> is a changed amino acid. --